Bio-Rad falls as weak 2026 outlook and post-earnings downgrades weigh on sentiment
Bio-Rad Laboratories shares are sliding as investors continue to reprice the stock after its Feb. 12, 2026 Q4/FY2025 report, which included a revenue miss and a muted 2026 outlook calling for only 0.5%–1.5% currency-neutral revenue growth. The decline is being reinforced by post-earnings downgrades to Hold that argued there is limited room for valuation multiple expansion after the weak guidance reset.
1. What’s moving the stock
Bio-Rad Laboratories (BIO) is down about 4% in the latest session as the market continues to digest the company’s latest earnings-and-outlook reset and adjusts expectations for 2026 growth. In its Feb. 12, 2026 fourth-quarter and full-year 2025 results release, Bio-Rad posted revenue slightly below consensus and paired it with a cautious 2026 framework that projected only 0.5%–1.5% currency-neutral revenue growth, keeping investors focused on sluggish end-market conditions and limited near-term acceleration. (investors.bio-rad.com)
2. Why selling pressure is persisting
The negative reaction has been extended by rating actions that followed the report. A recent downgrade to Hold framed the setup as unfavorable for valuation “multiple expansion” after the Q4 miss and what it characterized as weak 2026 guidance, even as it noted that portfolio actions could be a longer-dated catalyst. With incremental news flow limited, the stock’s day-to-day tape has been sensitive to sentiment shifts around life-science tools demand and funding conditions. (marketbeat.com)
3. What investors are watching next
Investors are monitoring whether Bio-Rad can stabilize the Life Science segment amid uneven biotech/biopharma spending, while sustaining momentum in Clinical Diagnostics. The next key checkpoints are order trends and instrument placements, commentary on academic and government funding dynamics, and any updates on margin execution against the company’s 2026 outlook. (morningstar.com)